Indoco Remedies

Indoco Remedies plunges 8% after warning letter from USFDA for Goa unit

Shares of Indoco Remedies plummeted up to 8.39 per cent at 312 per share on the BSE in Tuesday's intraday deals

Indoco Remedies zooms 5% after USFDA approval for anti-smoking drug

Indoco Remedies share price surged 5.42 per cent at Rs 317.80 a piece on the BSE after the company received a drug approval from the US regulator authority USFDA

Indoco Remedies shares rise over 3% on USFDA nod for allergy drug

Mumbai based pharmaceutical company Indoco Remedies share price surged 3.13 per cent at Rs 349.95 per share on the BSE

Indoco Remedies stock soars over 5% on USFDA approval for opioids drug

Indoco Remedies stock surged up to 5.53 per cent at Rs 358.60 per share on the BSE in Wednesday's intraday deals

BSE Healthcare hits new high; rallies 10% in 1 month on strong outlook

Solara Active Pharma Sciences, Indoco Remedies, Dishman Carbogen Amcis, Krishna Institute of Medical Sciences, Divi's Lab, Strides Pharma, Narayana Hrudayalaya and Vijaya Diagnostic were up 5 per cent

Indoco Remedies hits 8-month high on hopes of margin boost; stock surges 7%

In the past one week, it rallied 17 per cent, as against 0.35 per cent rise in the S&P BSE Sensex

Indoco Remedies gets final nod from US FDA for Lacosamide tablet

Pharmaceuticals firm Indoco Remedies Ltd on Tuesday said it has received final approval from the US health regulator for its generic Lacosamide tablet indicated for prevention and control of seizures. The approval granted by the US Food & Drug Administration (USFDA) for Lacosamide tablets is for strengths of 50 mg, 100 mg, 150 mg and 200 mg. These are the generic version of Vimpat Tablets of UCB Inc, the company said in a regulatory filing. Indoco Remedies Managing Director Aditi Kare Panandikar said, "The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide tablets has already reached the US". Lacosamide tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug, the company said. Citing IQVIA sales data for the period ending January 2022, the company ..

Indoco Remedies zooms 20%, hits record high on strong Q1 results

Indoco is expected to post strong FY22 top line growth as Domestic sales normalize and grow amid opportunities arising out of post-Covid complications, ICICI Securities said

Indoco Remedies zooms 20% on strong revenue from international business

The company's export formulations grew 65.6 per cent YoY to Rs 132 crore, driven by strong growth in regulated and emerging markets

Indoco Remedies rallies 9% after launching Covid treatment drug

Fevindo-400 will be made available at all government approved COVID care centres and selected medical practitioners across the country

Indoco Remedies surges 28% in 4 days post USFDA nod for Apixaban tablets

As per IMS MAT June'20 data, the US market size of Apixaban tablets is $11,037 million.

Indoco Remedies soars 19% on US FDA approval for Apixaban tablets

Apixaban is an anticoagulant, or blood thinner, used for patients with health problems caused by a blood clot

Indoco Remedies gets USFDA nod for blood thinning drug Apixaban tablets

Drug firm Indoco Remedies said it has received approval from the US health regulator for blood thinning drug Apixaban tablets

Indoco Remedies Q1 net profit jumps over nine-fold to Rs 17.04 cr

Drug firm Indoco Remedies on Tuesday reported over nine-fold jump in its consolidated net profit to Rs 17.04 crore for the first quarter ended June 30, mainly on account of robust sales.

Indoco Remedies gets USFDA warning letter for oral dosages plant in Goa

The company is committed to being cGMP-compliant and supplying quality products to its customers and the patients across the globe

Indoco Remedies slips 12% on warning letter from USFDA for Goa plant

The company will respond to the WL within stipulated time and is already working with CGMP consultant to ensure that the remediation activities are completed in line with the USFDA's expectations.

Indoco Remedies surges 43% in two days as Goa plant clears USFDA inspection

The stock surged 20% to Rs 239 on the NSE in early morning trade on Monday, rallying 43% in past two trading sessions.

Indoco Remedies zooms 20% as Goa plant clears USFDA inspection

The stock is locked in upper circuit of 20% at Rs 206 on the BSE after the US health regulator cleared inspection of the company's Goa plant II & III with two minor observations.

Indoco Remedies falls over 15% on import alert for Goa unit

The stock tanked 16% to Rs 208.50, also its 52-week low on the NSE in early morning trade

Indoco Remedies gains over 5% on acquisition of unit at Baddi

The stock up 6% to Rs 349 after the company announced it has acquired the manufacturing facility of Micro Labs located at Baddi.